AstraZeneca Reports Third Positive Phase III Result for Tozorakimab in COPD
AstraZeneca announced that its investigational IL-33–targeting antibody, tozorakimab, achieved a third successful Phase III trial in chronic obstructive pulmonary disease (COPD), reinforcing its potential as a new biologic treatment option. The latest MIRANDA trial showed a statistically significant reduction in moderate-to-severe COPD exacerbations, building on earlier positive results from the OBERON and TITANIA studies. These consistent outcomes highlight tozorakimab’s ability to deliver meaningful clinical benefit across a broad patient population, positioning it as a potential first-in-class therapy for COPD.
AstraZeneca Reports Third Positive Phase III Result for Tozorakimab in COPD